Stockreport

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst [Seeking Alpha]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. [Read more]